A Phase 1, Randomised, Placebo‑Controlled, Ascending Single and Multiple Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of PAT‑1251 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2017
At a glance
- Drugs PAT 1251 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors PharmAkea Therapeutics
- 22 Aug 2017 According to a PharmAkea Therapeutics media release, the data from this study will inform the dose selection and study design for a subsequent Phase 2 proof-of-concept study in Idiopathic-pulmonary-fibrosis.
- 22 Aug 2017 Results published in a PharmAkea Therapeutics media release.
- 28 Nov 2016 Status changed from recruiting to completed.